Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
doi:10.22028/D291-37254
Titel: | LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial |
VerfasserIn: | Ohlmann, Carsten-Henning Jäschke, Michelle Jaehnig, Peter Krege, Susanne Gschwend, Jürgen Rexer, Heidrun Junker, Kerstin Zillmann, Roger Rüssel, Christoph Hellmis, Eva Suttmann, Henrik Janssen, Martin Marin, Jan Hübner, Andreas Mathers, Michael Gleißner, Jochen Scheffler, Michael Feyerabend, Susan Telle, Jens Klier, Jörg Stöckle, Michael |
Sprache: | Englisch |
Titel: | Prostate Cancer and Prostatic Diseases |
Verlag/Plattform: | Springer |
Erscheinungsjahr: | 2022 |
Freie Schlagwörter: | Cancer therapy Prostate cancer |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | Background Although the benefit of androgen deprivation therapy (ADT) continuation in metastatic castration-resistant prostate cancer (mCRPC) remains controversial, clinical evidence is lacking. Recent results indicated that treatment with abiraterone acetate (AA) plus prednisone (P) further suppresses serum testosterone levels over ADT alone, suggesting that continuation of ADT in the treatment of mCRPC may not be necessary. Methods In this exploratory phase 2 study, mCRPC patients were randomized with a 1:1 ratio to receive either continued ADT plus AA + P (Arm A) or AA + P alone (Arm B). The primary endpoint was the rate of radiographic progression-free survival (rPFS) at month 12. Secondary endpoints included PSA-response rate, objective response, time to PSA progression and safety. Results A total of 68 patients were equally randomized between the two study arms. Median testosterone-levels remained below castrate-levels throughout treatment in all patients. According to the intention-to-treat analysis the rPFS rate was 0.84 in Arm A and 0.89 in Arm B. Moderate and severe treatment-emergent adverse events were reported for 72% of the patients in Arm A and for 85% of the patients in Arm B. Conclusions AA + P treatment without ADT may be effective in mCRPC patients and ADT may not be necessary in patients receiving AA + P. |
DOI der Erstveröffentlichung: | 10.1038/s41391-022-00533-6 |
URL der Erstveröffentlichung: | https://www.nature.com/articles/s41391-022-00533-6 |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-372547 hdl:20.500.11880/33769 http://dx.doi.org/10.22028/D291-37254 |
ISSN: | 1476-5608 1365-7852 |
Datum des Eintrags: | 16-Sep-2022 |
Bezeichnung des in Beziehung stehenden Objekts: | Supplementary information |
In Beziehung stehendes Objekt: | https://static-content.springer.com/esm/art%3A10.1038%2Fs41391-022-00533-6/MediaObjects/41391_2022_533_MOESM1_ESM.docx |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Urologie und Kinderurologie |
Professur: | M - Prof. Dr. Michael Stöckle |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Dateien zu diesem Datensatz:
Datei | Beschreibung | Größe | Format | |
---|---|---|---|---|
s41391-022-00533-6.pdf | 785,93 kB | Adobe PDF | Öffnen/Anzeigen |
Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons